Medpace Holdings, Inc.
MEDPNasdaq
$537.73
↓ -0.0%Jul 17 close · end-of-day
Price
1Y↑ +70.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$15.6B
Enterprise Value
$14.9B
P/E
33.8
P/S
5.8
P/B
26.0
EV/EBITDA
25.3
PEG
1.2
FCF Yield
4.6%
Dividend Yield
—
Revenue (TTM)
$2.7B
Net Income (TTM)
$460.4M
Free Cash Flow (TTM)
$711.0M
Gross Margin
—
Operating Margin
21.0%
Net Margin
17.2%
ROE
77.0%
ROIC
—
Debt / Equity
—
Net Cash
$652.7M
Return 1Y
+68.5%
Company profile
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company was founded in 1992 and is based in Cincinnati, Ohio.
- CEO
- August J. Troendle
- Sector
- Services
- Industry
- Business Services
- Employees
- 5,200
- Headquarters
- Ohio
- Website
- medpace.com
Management & directors
- Ewald Stephen PGeneral Counsel & Corp. Secy.
- Brady Kevin M.CFO & Treasurer
- Burwig Susan EExec. VP, Operations
- Geiger Jesse JPresident
- Troendle August J.CEO
Roles derived from SEC Form 4 filings.
Earnings
MEDP Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$706.6M↑ +26.5%
Diluted EPS$4.28↑ +16.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $925.9M | $1.1B | $1.5B | $1.9B | $2.1B | $2.5B |
| Gross profit | — | — | — | — | — | — |
| Operating income | $167.0M | $198.6M | $278.7M | $336.8M | $446.9M | $534.9M |
| Net income | $145.4M | $181.8M | $245.4M | $282.8M | $404.4M | $451.1M |
| Diluted EPS | $3.84 | $4.81 | $7.28 | $8.88 | $12.63 | $15.28 |
| Operating cash flow | $258.7M | $263.3M | $388.1M | $433.4M | $608.8M | $713.2M |
| Free cash flow | $227.3M | $235.1M | $351.2M | $396.7M | $572.3M | $681.9M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | 18.0% | 17.4% | 19.1% | 17.9% | 21.2% | 21.1% |
| Net margin | 15.7% | 15.9% | 16.8% | 15.0% | 19.2% | 17.8% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $528.1M | $533.3M | $536.6M | $558.6M | $603.3M | $659.9M | $708.5M | $706.6M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $105.2M | $112.3M | $125.4M | $113.5M | $126.3M | $141.8M | $153.3M | $141.5M |
| Net income | $88.4M | $96.4M | $117.0M | $114.6M | $90.3M | $111.1M | $135.1M | $123.9M |
| Diluted EPS | $2.75 | $3.01 | $3.67 | $3.67 | $3.10 | $3.86 | $4.65 | $4.28 |
| Operating cash flow | $116.4M | $149.1M | $190.7M | $125.8M | $148.5M | $246.2M | $192.7M | $151.8M |
| Free cash flow | $103.5M | $138.5M | $183.0M | $115.8M | $142.4M | $235.5M | $188.1M | $145.0M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 19.9% | 21.1% | 23.4% | 20.3% | 20.9% | 21.5% | 21.6% | 20.0% |
| Net margin | 16.7% | 18.1% | 21.8% | 20.5% | 15.0% | 16.8% | 19.1% | 17.5% |
Company news
Jul 11, 2026
Jul 8, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-30 | McCarthy Cornelius P. III | Option exercise | 28 | — | — | filing |
| 2026-06-30 | Kraft Robert O. | Option exercise | 33 | — | — | filing |
| 2026-06-30 | Carley Brian T | Option exercise | 36 | — | — | filing |
| 2026-05-28 | EWALD STEPHEN P· General Counsel & Corp. Secy. | Sale | 16,349 | $450.00 | $7.4M | filing |
| 2026-05-28 | EWALD STEPHEN P· General Counsel & Corp. Secy. | Option exercise | 16,349 | $138.87 | $2.3M | filing |
| 2026-04-24 | Brady Kevin M.· CFO & Treasurer | Option exercise | 7,000 | $138.87 | $972,090.00 | filing |
| 2026-04-24 | EWALD STEPHEN P· General Counsel & Corp. Secy. | Option exercise | 3,500 | $138.87 | $486,045.00 | filing |
| 2026-03-31 | McCarthy Cornelius P. III | Option exercise | 29 | — | — | filing |
| 2026-03-31 | Kraft Robert O. | Option exercise | 33 | — | — | filing |
| 2026-03-31 | Carley Brian T | Option exercise | 36 | — | — | filing |
| 2026-03-18 | BURWIG SUSAN E· Exec. VP, Operations | Option exercise | 12,000 | $166.73 | $2.0M | filing |
| 2026-03-17 | GEIGER JESSE J· President | Sale | 31,707 | $455.30 | $14.4M | filing |
| 2026-03-17 | GEIGER JESSE J· President | Option exercise | 31,707 | $138.87 | $4.4M | filing |
| 2026-02-17 | EWALD STEPHEN P· General Counsel & Corp. Secy. | Option exercise | 3,500 | $138.87 | $486,045.00 | filing |
| 2026-02-13 | BURWIG SUSAN E· Exec. VP, Operations | Option exercise | 10,984 | $107.93 | $1.2M | filing |
| 2026-02-13 | Carley Brian T | Option exercise | 6,472 | $54.99 | $355,895.28 | filing |
| 2025-12-31 | McCarthy Cornelius P. III | Option exercise | 49 | — | — | filing |
| 2025-12-31 | Kraft Robert O. | Option exercise | 56 | — | — | filing |
| 2025-12-31 | Carley Brian T | Option exercise | 62 | — | — | filing |
| 2025-12-05 | BURWIG SUSAN E· Exec. VP, Operations | Option exercise | 10,000 | $107.93 | $1.1M | filing |
| 2025-12-03 | Troendle August J.· CEO | Sale | 668 | $590.69 | $394,580.92 | filing |
| 2025-12-02 | Troendle August J.· CEO | Sale | 5,698 | $590.47 | $3.4M | filing |
| 2025-12-02 | BURWIG SUSAN E· Exec. VP, Operations | Option exercise | 10,000 | $107.93 | $1.1M | filing |
| 2025-12-01 | Troendle August J.· CEO | Sale | 23,178 | $593.25 | $13.8M | filing |
| 2025-11-28 | Troendle August J.· CEO | Sale | 15,151 | $593.46 | $9.0M | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.